AstraZeneca today announced that it will be moving three of its cancer compounds forward to Phase III clinical development. As set out at its Investor Day in March, oncology is one of the company's core therapy areas and accelerating the development of a number of new molecular entities in its pipeline is a strategic priority.
An ambitious new partnership to save the lives of a million of the poorest children in the world has been launched by GSK and Save the Children. This unique collaboration will see the two organisations work together in a very different way, sharing expertise, resources, reach and influence to tackle some of the leading causes of childhood deaths.
Novartis announced that the US Food and Drug Administration (FDA) has approved Ilaris® (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older. Ilaris is the first interleukin-1 beta (IL-1 beta) inhibitor approved for SJIA and the only treatment approved specifically for SJIA that is given as a once-monthly subcutaneous injection[1].
Amgen (NASDAQ:AMGN) and Zhejiang Beta Pharma Co., Ltd. (Zhejiang Beta Pharma) today announced that the companies have signed an agreement to form a joint venture to commercialize Amgen's Vectibix® (panitumumab) in the Chinese market. Together, Amgen and Zhejiang Beta Pharma aim to quickly and efficiently deliver Vectibix to patients in China.
Boehringer Ingelheim has joined the Structural Genomics Consortium (SGC). The consortium intends to promote research into protein structures and epigenetics that could pave the way for the development of novel therapies for previously uncurable diseases. As a member of the SGC, Boehringer Ingelheim will help fund precompetitive drug research aimed at bringing new, more effective medicines to patients faster.
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) announced that results from a prespecified subanalysis of the ARISTOTLE trial were published in Circulation, the peer-reviewed journal of the American Heart Association. Results from this subanalysis showed that the reductions in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis® (apixaban) compared to warfarin in the ARISTOTLE trial were consistent across subgroups defined based on levels of International Normalized Ratio (INR) control in patients with nonvalvular atrial fibrillation.
Most Read News
- Radioactive bacteria targets metastatic pancreatic cancer
- Drug reduces fat by blocking blood vessels
- Fighting bacteria with a new genre of antibodies
- Experts discuss ways to embed patient voices and values in clinical research
- Hundreds of alterations and potential drug targets to starve cancer tumors identified
- AstraZeneca first quarter results 2013
- Bristol-Myers Squibb reports first quarter 2013 financial results
Company Profiles and News
Showcase your Company Profile / News
Pharmaceutical Companies
News in Pictures
Be on top of World Pharma News!
Advertise with us - Download World Pharma News' Media Pack Read more
Abbott Launches New Psoriasisanswers.com Web site
August marks National Psoriasis Awareness Month, an opportunity to raise awareness about psoriasis, a skin disease that affects nearly 7.5 million Americans. For those living with this condition, finding information Read more
AstraZeneca Headquarters, London
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, Read more
Site Roche Basel
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in Read more
Gehry building, Novartis headquarters in Basel, Switzerland
Novartis provides healthcare solutions that address the evolving needs of patients and societies. Focused solely on healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving Read more
GSK Corporate HQ
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better Read more
Sanofi-aventis Group head office
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: Read more
Boehringer Ingelheim Center, Ingelheim, Germany
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 142 affiliates in 50 countries and more than 41,500 Read more
Novo Nordisk's corporate headquarters in Bagsværd, Denmark
Headquartered in Denmark, Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth Read more
Business & Industry News
- AstraZeneca issues update on accelerated oncology pipeline
- GSK and Save the Children form unique partnership to save the lives of one million children
- Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis
- Amgen and Zhejiang Beta Pharma announce planned joint venture in China
- Boehringer Ingelheim joins Structural Genomics Consortium
- Real-world data at ARVO highlight transformational outcomes seen with Lucentis®
- Bristol-Myers Squibb and Pfizer announce publication of ARISTOTLE subanalysis in Circulation
Research & Development News
- Breakup of physician, drug company relationship could improve health care, cut cost
- Nanotechnology could help fight diabetes
- First prospective trial shows molecular profiling timely for tailoring therapy
- Breakthrough in how pancreatic cancer cells ingest nutrients points to new drug target
- New class of drug targets skin cancer
- Study opens new prospects for developing new targeted therapies for breast cancer
- Experts discuss ways to embed patient voices and values in clinical research
Regulatory Affairs News
- FDA budget requests $4.7 billion
- FDA alerts health care providers of recall of anemia drug Omontys
- FDA approves Pomalyst for advanced multiple myeloma
- FDA approves Gleevec for children with acute lymphoblastic leukemia
- FDA approves new seasonal influenza vaccine made using novel technology
- FDA approves Eliquis to reduce the risk of stroke, blood clots in patients with non-valvular atrial fibrillation
- FDA expands use of Xarelto to treat, reduce recurrence of blood clots